2.20

0.00% 0.00

After Hours: 2.20

Acelyrin Inc (SLRN)

Overview News Price History Option Chain Why SLRN Down? Discussions Forecast

Acelyrin Inc stock is traded at $2.20, with a volume of 692.54K. It is up +0.00% in the last 24 hours and down -20.00% over the past month. Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Previous Close:

$2.20

Open:

$2.19

24h Volume:

692.54K

Relative Volume:

0.38

Market Cap:

$219.55M

Revenue:

Net Income/Loss:

$-299.80M

P/E Ratio:

-0.7746

EPS:

-2.84

Net Cash Flow:

$-217.49M

1W Performance:

+2.33%

1M Performance:

-20.00%

6M Performance:

-66.05%

1Y Performance:

-56.18%

1-Day Range:

$2.17

$2.23

1-Week Range:

$2.104

$2.3189

52-Week Range:

$1.845

$7.25

Acelyrin Inc Stock (SLRN) Company Profile

Name

Acelyrin Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

805-456-4393

Address

4149 LIBERTY CANYON RD., AGOURA HILLS

Employee

Twitter

Next Earnings Date

2025-03-31

Latest SEC Filings

SLRN's Discussions on Twitter

Compare SLRN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLRN Acelyrin Inc	2.20	219.55M	0	-299.80M	-217.49M	-2.84
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Acelyrin Inc Stock (SLRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Initiated	Wells Fargo	Equal Weight
Dec-08-23	Initiated	Citigroup	Neutral
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-05-23	Initiated	H.C. Wainwright	Buy
May-30-23	Initiated	Jefferies	Buy
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Piper Sandler	Overweight
May-30-23	Initiated	TD Cowen	Outperform

View All

Acelyrin Inc Stock (SLRN) Latest News

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 16, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve

Apr 16, 2025

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener

Apr 16, 2025

Apr 08, 2025

ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva

Apr 08, 2025

Apr 05, 2025

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times

Apr 05, 2025

Apr 04, 2025

Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa

Apr 04, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView

Apr 04, 2025

Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia

Apr 04, 2025

Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan

Apr 04, 2025

Apr 01, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve

Apr 01, 2025

Mar 28, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve

Mar 28, 2025

Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals

Mar 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Mar 28, 2025

Mar 27, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph

Mar 27, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN, TURN, BHLB, MHLD - TradingView

Mar 27, 2025

Mar 25, 2025

Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal

Mar 25, 2025

Mar 22, 2025

Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - MSN

Mar 22, 2025

Mar 21, 2025

TANG CAPITAL MANAGEMENT LLC Increases Stake in Acelyrin Inc - GuruFocus.com

Mar 21, 2025

Mar 20, 2025

ACELYRIN Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - The Manila Times

Mar 20, 2025

Mar 19, 2025

Insider Stock Sales Shake Up ACELYRIN, INC. - TipRanks

Mar 19, 2025

Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Acelyrin CEO Kim Mina sells $49,353 in company stock By Investing.com - Investing.com Canada

Mar 19, 2025

Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock - Investing.com

Mar 19, 2025

Acelyrin CEO Kim Mina sells $49,353 in company stock - Investing.com

Mar 19, 2025

ACELYRIN Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 19, 2025

Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock - Investing.com India

Mar 19, 2025

Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

ALUMIS INC. SEC 10-K Report - TradingView

Mar 19, 2025

Alumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial Results - Nasdaq

Mar 19, 2025

Alumis Doubles R&D Investment, Secures Game-Changing Merger Worth $737M - StockTitan

Mar 19, 2025

Mar 18, 2025